Abstract. Alternative splicing is a key mechanism that regulates protein diversity and has been found to be associated with colon cancer progression and metastasis. However, the function of alternative splicing in chemoradiation-resistant colon cancer remains elusive. In this study, we constructed a chemoradiation-resistant colon cancer cell line. Through RNA-sequencing of normal and chemoradiation-resistant colon cancer cells (HCT116), we found 818 genes that were highly expressed in the normal HCT116 cells, whereas 285 genes were highly expressed in the chemoradiation-resistant HCT116 (RCR-HCT116) cells. Gene ontology (GO) analysis showed that genes that were highly expressed in the HCT116 cells were enriched in GO categories related to cell cycle and cell division, whereas genes that were highly expressed in the RCR-HCT116 cells were associated with regulation of system processes and response to wounding. Analysis of alternative splicing events revealed that exon skipping was significantly increased in the chemoradiation-resistant colon cancer cells. Moreover, we identified 323 alternative splicing events in 293 genes that were significantly different between the two different HCT116 cell types. These alternative splicing-related genes were clustered functionally into several groups related with DNA replication, such as deoxyribonucleotide metabolic/catabolic processes, response to DNA damage stimulus and helicase activity. These findings enriched our knowledge by elucidating the function of alternative splicing in chemoradiation-resistant colon cancer.
Introduction
Alternative splicing of precursor mRNAs (pre-mRNAs) is critical for regulating transcriptome diversity and protein multiplicity. During the process of alternative splicing, exons are joined together to form different transcripts, leading to the synthesis of many more proteins (1) . It has been shown that alternative splicing occurs widely in eukaryotes. For example, 95% of intron-containing genes undergo alternative splicing in humans (2) . There are generally five different mechanisms of alternative splicing: exon skipping, mutually exclusive exons, alternative 3' splice site, alternative 5' splice site and intron retention. Among them, exon skipping is the most common mode, that is, almost 35% of human alternative splicing is caused by exon skipping. In addition to those basic modes of alternative splicing, there are some other methods such as multiple promoters and multiple polyadenylation sites in eukaryotes that also occur (3) (4) (5) .
Abnormally spliced mRNAs are found in many diseases, particularly in cancers. The number and types of alternative splicing differ in cancer cells compared with normal cells. For instance, cancer cells exhibit higher levels of intron retention but lower levels of exon skipping (6) (7) (8) (9) .
Colon cancer is the third leading cause of cancer-related deaths worldwide. Several studies have investigated the role of alternative splicing in colon cancer progression, and discovered that the number of alternative splicing increases during the transition from normal colon tissue to primary tumor, but decreases during metastasis to the liver (10) (11) (12) (13) . The differentially expressed alternative splicing genes in colon cancer are involved in cell-cell and cell-matrix interactions (14). Also, some alternative splicing genes have been identified because of their close association with cell growth and invasion in colon cancer, including SLC39A14, VEGF, CyclinD1, VCL, CALD1, and B3GNT6 (14, 15) . Since alternative splicing is crucial in colon cancer development, it is a promising target for novel anti-colon cancer therapeutics.
Preoperative chemoradiation therapy is a common and effective approach for cancer therapy, especially in colon Read filtering and mapping. RNA-seq raw data of the HCT116 and RCR-HCT116 cells were cleaned by removing the adaptor sequence and low quality reads (mapping quality <20). Clean reads were aligned to the human reference genome sequence hg19 using TopHat (19) . The following parameters were set: maximum number of mismatches permitted, 2; maximum alignments allowed, 20; maximum number of mismatches permitted in each segment alignment for reads mapped independently, 2; maximum insertion length, 3; maximum deletion length, 3; maximum mismatches in the anchor region, 0; min isoform-fraction, 0.15; minimum intron length, 50; maximum intron length, 50,000.
Differential expression analysis.
Genes that were differentially expressed between the two groups were defined as differentially expressed genes (DEGs). Cufflinks (20) software was used to calculate the fragments per kilobase of transcript per million fragments mapped (FPKM) value of the different genes. The DEGs from the normal and RCR-HCT116 cells were identified by Cuffdiff (20, 21) at a q≤0.01 and a fold change ≥2.
Identification and quantification of alternative splicing events. The alternative splicing events were classified into five patterns by the mixture of isoforms (MISO) (22) , including alternative 5' splice site, alternative 3' splice site, mutually exclusive exon, intron retention and exon skipping. The MISO Bayesian inference model was used for the quantification of alternative splicing events. The change of splicing isoforms was analyzed using the MISO Bayesian inference model. The significant differentially spliced events were determined by Bayes' factor (BF) and Psi values (percent-spliced-in, Ψ) (BF≥10 and Ψ≥0.2).
Gene ontology (GO) analysis. The hypergeometric distribution test was used to identify GO categories (biological process, cellular compartment and molecular function) that were significantly enriched in a specified gene set. GO analysis was implemented with Go.db package (23) .
Results

RNA-sequencing of normal and RCR-HCT116 cells.
In order to generate chemoradiation-resistant colon cancer cells, we first exposed the colon cancer-derived HCT116 cell line to 6 MV X-rays (4 Gy), and then incubated the cells in 10 µM 5-fluorouracil (5-FU). As shown in Fig. 1A , after a 24-h incubation, the medium was replaced with fresh medium to remove the apoptotic and dead cells. The cells were cultured in fresh medium until they were recovered and then treated with the same aforementioned method nine times.
Sequencing was performed on the Illumina HiSeq 4000 platform to generate 150-bp paired-end reads. After the removal of the adaptor sequence and the reads of low quality, a total of 162,398,220 and 134,409,494 reads of 101 bp were generated from the HCT116 and RCR-HCT116 cells, respectively. There were 80.28 and 80.30% of the total reads from HCT116 and RCR-HT116 cells mapped to the human reference genome (Fig. 1B , Table I ). Comparison of the RNA-seq data to the annotated human reference genome revealed that ~77% of the mapping reads were mapped to the CDS region. Meanwhile, the two RNA-seq libraries showed similar genomic distribution patterns from the mapping reads ( Fig. 2A) .
DEG screening.
To investigate the genes involved in chemoradiation resistance in colon cancer, we compared the RNA-seq data of the HCT116 and RCR-HCT116 cells to identify the DEGs. A total of 1,103 significant DEGs were identified (log 2 FC>1, FPKM1+FPKM2 >1, q<0.01), including 818 genes that were lowly expressed and 285 genes that were highly expressed in the RCR-HCT116 cells (Table II) .
GO enrichment analysis of DEGs. We then carried out GO enrichment analysis on the DEGs using Go.db package (23) , which calculates the p-values using hypergeometric distribution. Genes that were expressed at a lower level in the RCR-HCT116 cells than the level in the normal HCT116 cells were enriched for GO categories related to cell cycle and cell division (e.g. cell cycle, cell cycle phase, M phase, cell cycle process, mitosis and nuclear division); whereas genes that were expressed at a higher level in RCR-HCT116 cells than in the normal HCT116 cells were enriched for GO categories related to the regulation of system processes, response to wounding, Downregulated genes are genes that were expressed at a higher level in the HCT116 than in the RCR-HCT116 cells. upregulated genes are genes that were expressed at a higher level in the RCR-HCT116 than in the HCT116 cells. RCR-HCT116, chemoradiation-resistant HCT116 cells.
negative regulation of phosphorylation and regulation of phosphorylation (Table III) .
Identification and annotation of alternative splicing events.
To determine the relationship between sequencing depth and the detection power of alternative splicing, the sequencing libraries (HCT116 and RCR-HCT116 cells) were randomly selected to create sub-libraries (i.e. 5-95% of the whole library) to determine the known and novel junctions. As shown in Fig. 2B , the sequencing depth was correlated with the detection of unknown junctions, however, when the sequencing depth was more than 20% of the whole library, the increase of sequencing depth did not significantly increase the number of known junctions. This implies that our sequencing data was capable of supporting the identification of unknown junctions. We further examined the splicing patterns in the normal and chemoradiation-resistant colon cancer cells using the MISO (22) package. MISO quantifies the level of inclusion of a given differentially expressed exon as the 'percent spliced in' (Psi or Ψ), which reflects the fraction of a gene's mRNA that includes the exon, intron or alternative splice site. Ψ values vary between 0 (the exon, intron or alternative splice site is excluded from every transcript) and 1 (the exon, intron or alternative splice site is included in every transcript). MISO also calculates a Bayes factor for each differential splicing event, which is a measure of the odds that there is differential inclusion of a particular exon in different samples. The five main alternative splicing patterns, 3' splice site (A3SS), alternative 5' splice site (A5SS), mutually exclusive exon (MXE), intron retention (IR) and exon skipping (ES), were analyzed in the RNA-seq data of the HCT116 and the RCR-HCT116 cells (Fig. 3A) . Fig. 3B shows the Sashimi plots of five examples with different patterns of alternative splicing events, with the number of reads that span each part of the splice junction shown on the plots for the two samples analyzed. Furthermore we calculated the number of alternative splicing events for both types of cells and as shown in Fig. 3C , there was no significant difference in the number of detected A3SS, A5SS, MXE and IR in the normal and RCR-HCT116 cells, indicating that these types of alternative splicing may not function in chemoradiation-resistant colon cancer cells. Nevertheless, the number of ES was significantly increased in the chemoradiation-resistant colon cancer cells (Fig. 3C) , suggesting that chemoradiation may functions via ES.
Go enrichment analysis of genes with differentially alternative splicing levels.
To gain further insight into the role of these alternative splicing level altered genes, we performed GO analysis on the genes that had different alternative splicing levels in the normal and RCR-HCT116 cells. Our Fold enrichment, the ratio between the predicted and observed number of genes within the given GO category. Count, the number of genes observed in the given GO category. Category: BP, 'biological process'; MF, 'molecular function'; CC, 'cellular component'; GO, Gene ontology; RCR-HCT116, chemoradiation-resistant HCT116 cells.
dataset identified that 323 alternative splicing events in 293 genes were significantly different between the normal and RCR-HCT116 cells (data not shown). Some of the alternative splicing-containing genes were previously reported in colon cancers, such as CD44. Tumors carrying the CD44 v6 epitope (exon v6) acquire selective advantages during tumor progression. We further identified three new MXEs between exon 5 and exon 11 of CD44 (Fig. 4) , which may be associated with chemoradiation resistance of colon cancer. Go analysis showed that these genes were clustered functionally into several groups related with DNA replication, such as deoxyribonucleotide metabolic/catabolic processes (MPG, NT5M, RRM2B, OGG1, NT5C), response to DNA damage -stimulus (POLL, RECQL4, MPG, C17ORF70, PCBP4, POLG, ZMAT3, MuS81, GTF2H4, ZSWIM7, RRM2B, OGG1, ERCC3) and helicase activity (RECQL4, MOV10, DDX11, SKIV2L, EIF4A1, SNORA67, HLTF, ERCC3, SMARCA4) (Fig. 5) .
Discussion
Alternative splicing, a key molecular event that allows for protein diversity, is an important post-transcriptional regulatory mechanism to control cell processes. Aberrant splicing is related with various diseases, including colon cancer (24) (25) (26) . The importance of alternative splicing in colon cancer progression has been emphasized in many studies (24) . until now, many alternative splicing genes have been identified in colon cancer because of their close association with cell growth and invasion, including SLC39A14, VEGF, CyclinD1, VCL, CALD1, B3GNT6, ACTN1, TPM1, FN1, COL6A3, SLC3A2 (13) (14) (15) . Evidence suggests the role of CD44 alternative splicing in the progression of colon cancer. The expression of CD44 splice variants (exon v6) is increased during colon cancer progression and the expression level of CD44 v6 is associated with tumor-related mortality (27) (28) (29) . In this study, we identified three novel MXEs between the exon 5 and exon 11 of the CD44 gene. The levels of these MXEs were different between the normal and RCR-HCT116 cells, indicating that these novel alternative-splicing events occurring in CD44 may be related with the chemoradiation resistance of colon cancer. Thus, different alternative splicing events, that even exist on the same gene, may have diverse functions in tumor development and therapy. Preoperative chemoradiation therapy is increasingly used in colon cancer therapy (30, 31) . Some patients exhibit a marked pathologic response with standard chemoradiation treatment, however others remain non-responsive. Thus, the identification of markers that can predict sensitivity to chemoradiation is exceedingly useful to avoid unnecessary preoperative treatment. Previous studies have identified several markers that predict the sensitivity or resistance to chemoradiation therapy. A clinical study showed that thymidylate synthase (TS) is overexpressed in chemoradiation-resistant rectal cancer patients, which indicates that the level of TS in tumors is the best predictor of sensitivity to chemoradiation (31) . In our study, we identifed 323 alternative splicing events in 293 genes that were significantly different between the normal and chemoradiation-resistant HCT116 cells. Notably, there were no significant differences in the expression of most of these alternative splicing affected genes (26 out of 293, data not shown). It is deducible that apart from the expression level of some crucial genes, alternative-splicing events of these genes may also affect tumor sensitivity to chemoradiotherapy. In this study, we defined a set of 293 genes showing different alternative splicing events in a normal and chemoradiation-resistant colon cancer cell line. This group of genes were enriched in molecular functions and biological processes relevant to DNA replication, such as deoxyribonucleotide metabolic/catabolic processes and helicase activity. We identified for the first time, to the best of our knowledge, the alternative splicing events that are associated with the chemoradiation resistance of colon cancer. Thus, from a clinical point of view, our study is expected to provide insight into potential novel therapeutic targets, such as alternative splicing, to improve treatment response.
